1. Priortherapy for WM

2. Lymphoplasmacyticlymphoma with no detectable serum IgM paraprotein

3.   CNSinvolvement with WM

4.   Autoimmunecytopenias

5.   Majorsurgery within 4 weeks prior to randomisation

6.   Clinicallysignificant cardiac disease including the following:

o  Myocardialinfarction within 6 months prior to randomisation

o  Unstableangina within 3 months prior to randomisation

o  NewYork Heart Association class III or IV congestive heart failure

o  Historyof clinically significant arrhythmias (e.g. sustained ventricular tachycardia,ventricular fibrillation, torsades de pointes)

o  QTcF> 480 msecs based on Fredericia’s formula

o  Historyof Mobitz II second degree or third degree heart block without a permanentpacemaker in place

o  Uncontrolledhypertension as indicated by a minimum of 2 consecutive blood pressuremeasurements showing systolic blood pressure > 170 mmHg and diastolic bloodpressure > 105 mm Hg

o  Cardiacevent within 6 months of screening (e.g. coronary artery stent) requiring dualantiplatelet treatment

7.   Historyof stroke or intracranial haemorrhage within 6 months prior to randomisation

8.   Requiresanticoagulation with warfarin or equivalent vitamin K antagonists (direct oralanticoagulants (DOACs) allowed)

9.   Historyof severe bleeding disorders considered not to be disease related (HaemophiliaA, B or von Willebrand’s disease)

10. Requires ongoing treatment with a strongCYP3A inhibitor or inducer

11. Known infection with HIV, or serologicstatus reflecting active hepatitis B or C infection as follows:

o  Presenceof hepatitis B surface antigen (HBsAg). In addition, if negative for HBsAg butHBcAb positive (regardless of HBsAb status), a HB DNA test will be performedand if positive the patient will be excluded

o  Presenceof hepatitis C virus (HCV) antibody. Patients with presence of HCV antibody areeligible if HCV RNA is undetectable

12. Women who are pregnant or breastfeedingor males expecting to conceive or father children at any point from the startof treatment until the end of the “at risk period” – see section 12.7 fordetails

13. Renal failure (creatinine clearance

14. Patients with chronic liver disease withhepatic impairment Child-Pugh class B or C

15. Known history of anaphylaxis to any ofthe IMPs or its excipients, in addition to murine derived monoclonalantibodies.

16. Received live vaccine six weeks prior tofirst dose of study therapy

17. Inability to swallow oral medication

18. Disease significantly affectinggastrointestinal function and/or inhibiting small intestine absorption (e.g. malabsorptionsyndrome, resection of the small bowel, poorly controlled inflammatory boweldisease)

19. Active systemic infection requiringtreatment

20. Concomitant treatment with anotherinvestigational agent

21. Any life-threatening illness, medicalcondition, organ system dysfunction, need for profound anticoagulation, orbleeding disorder, which, in the investigator’s opinion, could compromise the patient’ssafety, or put the study at risk

22. Unwilling or unable to take PJP prophylaxis(e.g. cotrimoxazole)

23. History of prior malignancy, with theexception of the following:

o  Malignancytreated with curative intent and with no evidence of active disease present formore than 3 years prior to screening and felt to be at low risk for recurrenceby treating physician 

o  Adequately treated non-melanomatous skin cancer or lentigomaligna melanoma, superficial bladder cancer, carcinoma in situ of the cervixor breast or localized Gleason score 6 prostate cancer without current evidenceof disease.